Comparison of AMG 416 and cinacalcet in rodent models of uremia

BMC Nephrology

Volumn 15, Issue 1, 2014, Pages

  Walter, Sarah ^a,b   Baruch, Amos ^a,c   Alexander, Shawn T ^a   Janes, Julie ^a,d   Sho, Eiketsu ^a,e   Dong, Jin ^a,f   Yin, Qun ^a,g   Maclean, Derek ^a   Mendel, Dirk B ^a,f   Karim, Felix ^a   Johnson, Randolph M ^a  

^a AMGEN INC   (United States)

^b TEVA PHARMACEUTICALS   (Israel)

^c GENENTECH INC   (United States)

^d Calithera Biosciences   (United States)

^e Kunming Biomed International   (China)

^f MEDIMMUNE   (United States)

^g Sutro Biopharma   (United States)

Author keywords

AMG 416; Calcium sensing receptor; Chronic kidney disease (CKD); Secondary hyperparathyroidism (SHPT); Uremic rat model

Indexed keywords

CALCIUM; CINACALCET; CREATININE; PARATHYROID HORMONE; VELCALCETIDE; AMG-416; CALCIMIMETIC AGENT; CALCIUM SENSING RECEPTOR; NAPHTHALENE DERIVATIVE; PEPTIDE;

ACUTE KIDNEY FAILURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CALCIUM BLOOD LEVEL; CHRONIC KIDNEY DISEASE; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DISEASE SEVERITY; MALE; NEPHRECTOMY; NONHUMAN; PARATHYROID HORMONE BLOOD LEVEL; RAT; SINGLE DRUG DOSE; TREATMENT DURATION; UREMIA; AGONISTS; ANIMAL; CONVALESCENCE; DISEASE MODEL; DRUG EFFECTS; HUMAN; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT; TREATMENT OUTCOME;

ANIMALS; CALCIMIMETIC AGENTS; DISEASE MODELS, ANIMAL; HUMANS; MALE; NAPHTHALENES; PEPTIDES; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, CALCIUM-SENSING; RECOVERY OF FUNCTION; TREATMENT OUTCOME; UREMIA;

EID: 84901331394     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-15-81     Document Type: Article

References (17)

1. Endocrine functions of bone in mineral metabolism regulation. Quarles LD, J Clin Invest 2008 118 12 3820 3828 10.1172/JCI36479 19033649
2. Cloning and characterization of an extracellular Ca(2+)-sensing receptor from bovine parathyroid. Brown EM, Gamba G, Riccardi D, Lombardi M, Butters R, Kifor O, Sun A, Hediger MA, Lytton J, Hebert SC, Nature 1993 366 6455 575 580 10.1038/366575a0 8255296 (Pubitemid 24035999)
3. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG, N Engl J Med 2004 350 15 1516 1525 10.1056/NEJMoa031633 15071126 (Pubitemid 38477776)
4. Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, Colloton M, Karbon W, Scherrer J, Shatzen E, Rishton G, Scully S, Qi M, Harris R, Lacey D, Martin D, J Pharm Exp Ther 2004 308 2 627 635 (Pubitemid 38134225)
5. Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. Walter S, Baruch A, Dong J, Tomlinson JE, Alexander ST, Janes J, Hunter T, Yin Q, Maclean D, Bell G, Bell G, Mendel DB, Johnson RM, Karim F, J Pharm Exp Ther 2013 346 2 229 240 10.1124/jpet.113.204834
6. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients. Martin KJ, Pickthorn K, Huang S, Block GA, Vick A, Mount PF, Power DA, Bell G, Kidney Int 2013
7. Martin KJ, Bell G, Pickthorn K, Huang S, Hodsman P, Peacock M, Characterization of KAI-4169, a novel peptide for the treatment of chronic kidney disease-mineral and bone disorder, in a phase 1 study in healthy males. ASN PO1238 (ASN Meeting 2011)
8. Regulation of bone remodeling by the central and peripheral nervous system. Elefteriou F, Arch Biochem Biophys 2008 473 2 231 236 10.1016/j.abb.2008.03.016 18410742
9. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism. Colloton M, Shatzen E, Miller G, Stehman-Breen C, Wada M, Lacey D, Martin D, Kidney Int 2005 67 2 467 476 10.1111/j.1523-1755. 2005.67103.x 15673294 (Pubitemid 40139838)
10. The pathogenesis of parathyroid gland hyperplasia in chronic renal failure. Drueke TB, Kidney Int 1995 48 1 259 272 10.1038/ki.1995.292 7564087
11. Destabilization of parathyroid hormone mRNA by extracellular Ca2+ and the calcimimetic R-568 in parathyroid cells: role of cytosolic Ca and requirement for gene transcription. Ritter CS, Pande S, Krits I, Slatopolsky E, Brown AJ, J Mol Endocrinol 2008 40 1 13 21 10.1677/JME-07-0085 18096993 (Pubitemid 351279505)
12. Pharmacokinetics and pharmacodynamics of cinacalcet in hepatic impairment: phase I, open-label, parallel-group, single-dose, single-centre study. Padhi D, Harris RZ, Salfi M, Noveck RJ, Sullivan JT, Clin Drug Invest 2008 28 10 635 643 10.2165/00044011-200828100-00004
13. KAI-4169, a Novel Calcium Sensing Receptor Agonist, Decreses Serum iPTH, FGF-23 and Improves Serum Bone Markers in a Phase 2 Study in Hemodialysis Subjects with Chronic Kidney-Disease-Mineral and Bone Disorder. Block GA BG, Pickthorn K, Huang S, Martin KJ, 49th ERA-EDTA Congress: May 26, 2012 2012; Paris, France 2012
14. Cinacalcet suppresses calcification of the aorta and heart in uremic rats. Kawata T, Nagano N, Obi M, Miyata S, Koyama C, Kobayashi N, Wakita S, Wada M, Kidney Int 2008 74 10 1270 1277 10.1038/ki.2008.407 18813289
15. 1,25-Dihydroxyvitamin D3 but not cinacalcet HCl (Sensipar/Mimpara) treatment mediates aortic calcification in a rat model of secondary hyperparathyroidism. Henley C, Colloton M, Cattley RC, Shatzen E, Towler DA, Lacey D, Martin D, Nephrol Dial Transplant 2005 20 7 1370 1377 10.1093/ndt/gfh834 15855208 (Pubitemid 41430610)
16. Clinical pharmacokinetic and pharmacodynamic profile of cinacalcet hydrochloride. Padhi D, Harris R, Clin Pharmacokinet 2009 48 5 303 311 10.2165/00003088-200948050-00002 19566113
17. Cinacalcet increases calcium excretion in hypercalcemic hyperparathyroidism after kidney transplantation. Borchhardt KA, Heinzl H, Mayerwoger E, Horl WH, Haas M, Sunder-Plassmann G, Transplantation 2008 86 7 919 924 10.1097/TP.0b013e318186b7fb 18852656